Physician profile
Theodore Rosen
NPI 1881790749
$46,540.64
in general payments reported to CMS, 2019-2025
16 companies · $5,535 in 2025
The $5,535 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $26K · 2022: $40.00 · 2024: $1,432 · 2025: $5,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,320 · Consulting Fee: $1,300 · Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,320.00 |
| Consulting Fee | $1,300.00 |
| Food and Beverage | $347.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $15,896.86 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11,878.44 | 2019-2020 | |
| Genzyme Corporation | $5,320.00 | 2025 | |
| Parapro, LLC | $4,000.00 | 2020 | |
| Vyne Pharmaceuticals INC. | $2,505.90 | 2020 | |
| Leo Pharma INC. | $2,200.00 | 2020 | |
| Glenmark Pharmaceuticals Limited | $1,500.00 | 2020 | |
| Verrica Pharmaceuticals INC. | $1,393.19 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $1,348.77 | 2019 | |
| Incyte Corporation | $155.68 | 2025 | Opzelura |
| Genentech USA, INC. | $100.00 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $89.64 | 2019-2025 | |
| Aclaris Therapeutics, INC. | $60.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.74 | 2024 | |
| Genentech, INC. | $38.00 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.